Our biomedical imaging research over the last 20 years has led to the discovery of small molecular necrosis-avid compounds (NACs) useful for imaging diagnosis of myocardial infarction and therapeutic assessment of RF tumor ablation with MRI, nuclear scintiscan and optical imaging.This stroma targetability has now been extended from diagnostic to therapeutic utilities in combination with the use of vascular disrupting agents (VDAs) to formulate a novel anticancer approach namely small-molecular sequential dual targeting theragnostic strategy (SMSDTTS), in which instead of directly attacking cancer cells (seeds), we sought to treat solid malignant tumors by selectively destroying their microenvironment (soil).